UK markets closed
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • FTSE 250

    17,168.34
    +377.94 (+2.25%)
     
  • AIM

    806.38
    +7.99 (+1.00%)
     
  • GBP/EUR

    1.1381
    +0.0057 (+0.50%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • BTC-GBP

    17,275.34
    -153.65 (-0.88%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • DOW

    28,725.51
    -500.10 (-1.71%)
     
  • CRUDE OIL

    79.74
    -1.49 (-1.83%)
     
  • GOLD FUTURES

    1,668.30
    -0.30 (-0.02%)
     
  • NIKKEI 225

    25,937.21
    -484.84 (-1.83%)
     
  • HANG SENG

    17,222.83
    +56.96 (+0.33%)
     
  • DAX

    12,114.36
    +138.81 (+1.16%)
     
  • CAC 40

    5,762.34
    +85.47 (+1.51%)
     

Global Pharmaceutical Contract Development & Manufacturing Market Report to 2027 - Featuring AbbVie, Almac, Catalent and Danaher Among Others

·3-min read
Company Logo
Company Logo

Pharmaceutical Contract Development & Manufacturing Market

Pharmaceutical Contract Development & Manufacturing Market
Pharmaceutical Contract Development & Manufacturing Market

Dublin, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Development & Manufacturing Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The Global Pharmaceutical Contract Development & Manufacturing Market is projected to reach USD 176.91 billion by 2027 from USD 107.61 billion in 2021, at a CAGR 8.63% during the forecast period.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

  • The Americas Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 37,848.04 million in 2021, is expected to reach USD 40,998.19 million in 2022, and is projected to grow at a CAGR of 8.59% to reach USD 62,062.90 million by 2027.

  • The Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 32,241.32 million in 2021, is expected to reach USD 35,132.97 million in 2022, and is projected to grow at a CAGR of 8.80% to reach USD 53,490.17 million by 2027.

  • The Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market size was estimated at USD 37,525.20 million in 2021, is expected to reach USD 40,589.67 million in 2022, and is projected to grow at a CAGR of 8.54% to reach USD 61,358.02 million by 2027.

Market Segmentation & Coverage:

The report on pharmaceutical contract development & manufacturing identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making.

This market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

This research report categorizes the pharmaceutical contract development & manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

Service:

  • Biologics Manufacturing Services

    • Biologics API Manufacturing Services

    • Biologics FDF Manufacturing Services

  • Drug Development Services

  • Pharmaceutical Manufacturing Services

    • Pharmaceutical API Manufacturing

      • Capsule Manufacturing Services

      • Oral Liquid Manufacturing Services

      • Parenteral/Injectable Manufacturing Services

      • Tablet Manufacturing Services

    • Pharmaceutical FDF Manufacturing

  • Secondary Packaging Services

End User:

  • Big Pharma

  • Generic Pharmaceutical Companies

  • Small & Mid-Size Pharma

Region:

  • Americas

    • Argentina

    • Brazil

    • Canada

    • Mexico

    • United States

      • California

      • Florida

      • Illinois

      • New York

      • Ohio

      • Pennsylvania

      • Texas

  • Asia-Pacific

    • Australia

    • China

    • India

    • Indonesia

    • Japan

    • Malaysia

    • Philippines

    • Singapore

    • South Korea

    • Taiwan

    • Thailand

  • Europe, Middle East & Africa

    • France

    • Germany

    • Italy

    • Netherlands

    • Qatar

    • Russia

    • Saudi Arabia

    • South Africa

    • Spain

    • United Arab Emirates

    • United Kingdom

Company Usability Profiles:

  • AbbVie, Inc.

  • Aenova Group GmbH

  • Almac Group

  • AMRI Global

  • C.H. Boehringer Sohn AG & Ko. KG

  • Cambrex Corporation

  • Catalent, Inc.

  • Danaher Corporation

  • Delwis Healthcare Pvt Ltd.

  • Evonik Industries AG

  • Famar Health Care Services

  • Fareva

  • Jubilant Life Sciences Limited

  • Lonza Group AG

  • Pfizer Inc.

  • Recipharm AB

  • Serum Institute of India Ltd.

  • Siegfried Holding AG

  • Thermo Fisher Scientific Inc.

  • Vetter Pharma-Fertigung GmbH & Co. KG

For more information about this report visit https://www.researchandmarkets.com/r/ygj1w

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900